Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate (NMDA) receptor antagonist which reduces glutamatergic excitotoxicity. Benefits are seen in cognitive, functional and global measures in both outpatients and nursing home residents. Prospective health economic benefits have been reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12968/hosp.2003.64.11.2346 | DOI Listing |
Publication Analysis
Top Keywords
memantine ebixa
4
ebixa stages
4
stages dementia
4
dementia memantine
4
memantine agent
4
agent licensed
4
licensed treatment
4
treatment moderate
4
moderate severe
4
severe alzheimer's
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!